<DOC>
	<DOCNO>NCT00697229</DOCNO>
	<brief_summary>The purpose study evaluate safety , immunogenicity reactogenicity MPL-adjuvanted recombinant hepatitis B vaccine comparison Engerix™-B healthy adult volunteer follow two different schedule : 0 , 2 month 0 , 6 month</brief_summary>
	<brief_title>Immunogenicity &amp; Reactogenicity HBV-MPL Vaccine Engerix™-B Healthy Adults Following 2 Different Schedules</brief_title>
	<detailed_description>At time conduct study , sponsor GlaxoSmithKline know former name SmithKline Beecham</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Between 18 40 year old . Written inform consent obtain subject . Good physical condition establish physical examination history take time entry . Female participant avoid become pregnant study period contraceptive program least 2 month entry . Positive titre anti hepatitis B antibody . Any vaccination hepatitis B past . Elevated serum liver enzymes . History significant persisting hematologic , hepatic , renal , cardiac respiratory disease . Axillary temperature &gt; 37°C time injection . Any acute disease moment entry . Chronic alcohol consumption . Any chronic drug treatment , include treatment immunosuppressive drug , investigator 's opinion , preclude inclusion study . History allergic disease likely stimulate component vaccine . Administration vaccine ( ) immunoglobulin study period . Simultaneous participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Engerix™-B</keyword>
	<keyword>Recombinant hepatitis B vaccine</keyword>
</DOC>